Transtech Ophthalmology -B(06622): Presbyopia innovative drug YUVEZZI approved by the Macau Special Administrative Region Government's Drug Regulatory Authority.

Financial APP News from Wisdom Finance, Megi Eye Care-B (06622) announced that on July 13, 2026, the company's innovative drug YUVEZZI (2.75% carbidine and 0.1% bromonidene tartrate eye drops) has been approved by the Macao Special Administrative Region Government Drug Administration for the treatment of presbyopia.